sale to GHO Capital Partners LLP
Baird served as exclusive financial advisor to DNA Diagnostics Center on this transaction.
AboutDNA Diagnostics Center (“DDC” or “the Company”), a portfolio company of MTS Health Investors, LLC (“MTS”) and Oaktree Capital Management, L.P. ("Oaktree"), was recently acquired by Global Healthcare Opportunities (“GHO Capital Partners LLP” or “GHO”) for $110 million.
DDC is a market leading diagnostics business and is one of the world’s largest providers of private DNA testing services. The Company’s platform technology offers a wide range of products in the fields of biological family relationship testing, veterinary services, forensic services and medical applications for the pharmaceutical industry including cell-line authentication. DDC currently processes over 750,000 tests per annum in its state-of-the-art facility and is consistently recognized as the laboratory of choice for high quality results and excellence in customer service. DDC is headquartered in Fairfield, Ohio.
MTS Health Investors, LLC is a healthcare private equity firm that makes investments in operating companies within the healthcare industry. MTS focuses on companies that deliver greater value for every dollar spent in healthcare. Industry sectors in which MTS invests include: providers of outsourced solutions to the healthcare industry; providers of direct medical services to patients in an institutional, ambulatory, or home setting; providers of managed care and other healthcare insurance services; distributors of medical products; and manufacturers of low-technology medical devices and supplies. MTS is located in New York, New York.
GHO Capital Partners LLP was founded in 2014 as a specialist healthcare investment adviser. GHO’s vision is to apply global capabilities and perspectives to build a world-class healthcare specialist private equity firm by recognizing and seizing the highly attractive and underpenetrated European market opportunity. GHO is based in London, United Kingdom.
Oaktree Capital Management is a leading global alternative investment management firm with particular expertise in credit strategies. The firm was formed in 1995 by a group of individuals who had been investing together since the mid-1980s in high yield bonds, convertible securities, distressed debt, real estate and control investments. Today, Oaktree has over 900 employees in Los Angeles (headquarters), London, New York, Hong Kong, Stamford, Houston, Tokyo, Luxembourg, Paris, Frankfurt, Singapore, Seoul, Beijing, Amsterdam, Dublin, Dubai and Shanghai.
For additional information about this transaction, please contact:
- October 2015
- DNA Diagnostics Center
- Target Location
- North America
- Acquiror Location